What is the pathogenesis of clevidipine toxicity?

Updated: Jan 04, 2021
  • Author: B Zane Horowitz, MD, FACMT; Chief Editor: Michael A Miller, MD  more...
  • Print

Clevidipine (Cleviprex) is a dihydropyridine L-type CCB administered intravenously. It is rapidly distributed and metabolized and therefore has a very short half-life (terminal half-life of approximately 15 min). L-type calcium channels mediate the influx of calcium during depolarization in arterial smooth muscle. Clevidipine reduces mean arterial blood pressure by decreasing systemic vascular resistance. It does not reduce cardiac filling pressure (preload), confirming a lack of effects on the venous capacitance vessels.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!